VMC Fast-Hash One Prospector Review – 512gh/s bitcoin mining machine with 28nm ASIC. – Video

Posted on by


VMC Fast-Hash One Prospector Review - 512gh/s bitcoin mining machine with 28nm ASIC.
Review of the Virtual Mining Corp 28nm ASIC Bitcoin Miner called the "Fast Hash One Prospector" Latest model available here: http://virtualminingcorp.com/shop1/index.php?id_product=41 controller=p...

By: CryptoCurrency

Continue reading here:

VMC Fast-Hash One Prospector Review - 512gh/s bitcoin mining machine with 28nm ASIC. - Video

Workington Comets' Bach to ride through pain barrier

Posted on by

by John Fuller

Last updated at 11:23, Friday, 09 May 2014

Rene Bach will ride through the pain to ensure Workington Comets progress in the Knock-Out Cup.

Rene Bach

The west Cumbrian side have a 14-point lead going into tonights first round second leg at Somerset.

Captain Bach is still recovering from the hip injury he picked up in the Danish Champiomship semi-final last week. He made his track return earlier this week, but admitted being sore afterwards.

Comets will, however, be without Ashley Morris and Ricky Wells, who are riding for parent club Wolverhampton.

Newcastles in-form Lewis Rose with rider replacement being operated for Wells.

Team manager Tony Jackson said: We realise that this will be a very difficult meeting and of course Somerset know exactly what they need to do to overhaul us and will no doubt try to hit us hard from the start.

We will simply forget about the first leg and look at it as a match we want to win, which hopefully will keep our aggregate lead, or much of it, intact and get us over the finish line.

View original post here:

Workington Comets' Bach to ride through pain barrier

Amgen-AstraZeneca Experimental Medicine Eases Psoriasis

Posted on by

Amgen Inc. (AMGN) and AstraZeneca Plc (AZN)s experimental drug brodalumab eased symptoms of psoriasis at both doses tested in a key study needed for U.S. approval.

The medicine for moderate to severe plaque psoriasis dispersed the thick red patchy scales on patients skin, leaving it markedly clearer than those getting a placebo, the companies said today in a statement. The study is the first from the final round of tests on the drug. Two studies comparing it with Johnson & Johnsons Stelara are expected by year end, said Sean Harper, executive vice president of research and development for Amgen, the worlds biggest biotechnology company by revenue.

The psoriasis drug is part of a 2012 collaboration between Thousand Oaks, California-based Amgen and London-based AstraZeneca to develop five medicines from Amgens portfolio of therapies for inflammation. AstraZeneca is currently grappling with a $106 billion acquisition bid from Pfizer Inc., which executives rejected last week as too low because it undervalued the U.K. companys drug pipeline.

Brodalumab works in a different manner than existing drugs and rivals in development, latching on to the interleukin 17 receptor and blocking inflammation thats a key driver of the disease. Novartis AG and Eli Lilly & Co. are also working on medicines to treat psoriasis, which would compete with drugs including J&Js Stelara and Amgens Enbrel.

The study of 661 patients found 83 percent in the high-dose brodalumab arm and 60 percent getting a lower dose had the severity of their disease lessen by at least 75 percent after three months of treatment, compared with a similar benefit in 2.7 percent of patients given a placebo.

About 125 million people worldwide suffer from the skin condition, including about 7.5 million Americans, according to the National Psoriasis Foundation.

To contact the reporter on this story: Michelle Fay Cortez in Minneapolis at mcortez@bloomberg.net

To contact the editors responsible for this story: Reg Gale at rgale5@bloomberg.net Andrew Pollack, Angela Zimm

View post:

Amgen-AstraZeneca Experimental Medicine Eases Psoriasis

Amgen, AstraZeneca Say Ph 3 Study Of Psoriasis Drug Brodalumab Meets Goals

Posted on by

By RTT News, May 09, 2014, 04:18:00 PM EDT

(RTTNews.com) - Amgen Inc. ( AMGN ) and AstraZeneca PLC (AZN, AZN.L) said Friday that the Phase 3 AMAGINE-1 study evaluating brodalumab in patients with moderate-to-severe plaque psoriasis met all primary and secondary endpoints for both evaluated doses.

Brodalumab is the only investigational treatment in development that binds to the interleukin-17 receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor.

Primary endpoints were patients achieving at least a 75% improvement from baseline in disease severity at week 12, as measured by the Psoriasis Area Severity Index, and patients achieving clear or almost clear skin at week 12 according to the static Physician Global Assessment.

Psoriasis is a non-contagious chronic disease in which the immune system causes skin cells to grow at an accelerated rate. Instead of being shed, skin cells pile up, causing painful and itchy, red, scaly patches.

AMAGINE-1 is one of three Phase 3 studies designed to assess the efficacy and safety of brodalumab in patients with moderate-to-severe plaque psoriasis. AMAGINE-2 and AMAGINE-3 are designed to evaluate the efficacy and safety of induction and maintenance regimens of brodalumab at different dose schedules in patients with moderate-to-severe plaque psoriasis compared to ustekinumab and placebo.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com

Go here to see the original:

Amgen, AstraZeneca Say Ph 3 Study Of Psoriasis Drug Brodalumab Meets Goals